Reckitt Benckiser kicks off USD 10 billion infant nutrition business sale: Bloomberg
Bids for the business, whose biggest operations are in the US, are expected at the end of May, the people said.
New Delhi: Reckitt Benckiser Group Plc has begun a sale process for its infant nutrition business in what's set to be one of the British consumer goods firm's largest-ever disposals, people with knowledge of the matter said.
The London-listed company, which sells brands including Enfamil formula, sent out marketing materials to potential buyers this month, the people said. Reckitt could seek as much as $10 billion for the unit, according to the people, who asked not to be identified because the information is private.
Bids for the business, whose biggest operations are in the US, are expected at the end of May, the people said. It could attract interest mostly from private equity firms, the people said.
A sale would complete a reversal of Reckitt's largest purchase, the $17 billion acquisition of Mead Johnson Nutrition Co. five years ago under former Chief Executive Officer Rakesh Kapoor. His successor, Laxman Narasimhan, sold the Chinese infant formula part of that business to local buyout firm Primavera Capital for $2.2 billion last year, exiting one of its largest markets.
The company said at the time that the remaining operations in North America and other parts of the world had about 5.4 billion pounds ($7.3 billion) of net assets.
Read also: Reckitt Benckiser rebrands itself as Reckitt
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.